Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID)

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 5, 2016, Pages 1008-1017

  Hainsworth, Atticus H ^a   Yeo, Natalie E ^a   Weekman, Erica M ^b   Wilcock, Donna M ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Brain; Dementia; Homocysteine; Hyperhomocysteinemia; Vascular cognitive impairment

Indexed keywords

COLLAGEN; CYSTATHIONINE BETA SYNTHASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HOMOCYSTEIC ACID; HOMOCYSTEINE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BASEMENT MEMBRANE; BIOCHEMICAL ANALYSIS; BLOOD BRAIN BARRIER; BRAIN SYNAPTOSOME; CELL PROLIFERATION; COGNITION; COGNITIVE AGING; COGNITIVE DEFECT; COLLAGEN DISEASE; COLLAGEN SYNTHESIS; CONTROLLED CLINICAL TRIAL (TOPIC); DEMENTIA; DISEASE COURSE; DNA SYNTHESIS; DOPAMINERGIC NERVE CELL; EC50; ENDOPLASMIC RETICULUM; ENDOTHELIUM CELL; GENE INDUCTION; HUMAN; HYPERHOMOCYSTEINEMIA; IC50; LIPID PEROXIDATION; META ANALYSIS (TOPIC); MITOGENESIS; MOUSE; MUSCLE CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; SOCIAL ISOLATION; SPATIAL LEARNING; SYSTEMATIC REVIEW (TOPIC); VASCULAR FIBROSIS; VASCULAR SMOOTH MUSCLE CELL; VITAMIN SUPPLEMENTATION;

EID: 84950161678     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.11.015     Document Type: Article

References (125)

1. Aisen P.S., Schneider L.S., Sano M., az-Arrastia R., van Dyck C.H., Weiner M.F., Bottiglieri T., Jin S., Stokes K.T., Thomas R.G., Thal L.J. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008, 300:1774-1783.
2. Albrecht J., Dolinska M., Hilgier W., Lipkowski A.W., Nowacki J. Modulation of glutamine uptake and phosphate-activated glutaminase activity in rat brain mitochondria by amino acids and their synthetic analogues. Neurochem. Int. 2000, 36:341-347.
3. Allen I.C., Schousboe A., Griffiths R. Effect of l-homocysteine and derivatives on the high-affinity uptake of taurine and GABA into synaptosomes and cultured neurons and astrocytes. Neurochem. Res. 1986, 11:1487-1496.
4. Baumbach G.L., Sigmund C.D., Bottiglieri T., Lentz S.R. Structure of cerebral arterioles in cystathionine beta-synthase-deficient mice. Circ. Res. 2002, 91:931-937.
5. Bernardo A., McCord M., Troen A.M., Allison J.D., McDonald M.P. Impaired spatial memory in APP-overexpressing mice on a homocysteinemia-inducing diet. Neurobiol. Aging 2007, 28:1195-1205.
6. Beydoun M.A., Beydoun H.A., Gamaldo A.A., Teel A., Zonderman A.B., Wang Y. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health 2014, 14:643.
7. Brown J.C., Rosenquist T.H., Monaghan D.T. ERK2 activation by homocysteine in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 1998, 251:669-676.
8. Budni J., Zomkowski A.D., Engel D., Santos D.B., dos Santos A.A., Moretti M., Valvassori S.S., Ornell F., Quevedo J., Farina M., Rodrigues A.L. Folic acid prevents depressive-like behavior and hippocampal antioxidant imbalance induced by restraint stress in mice. Exp. Neurol. 2013, 240:112-121.
9. Casas J.P., Bautista L.E., Smeeth L., Sharma P., Hingorani A.D. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005, 365:224-232.
10. Chambers J.C., Ueland P.M., Obeid O.A., Wrigley J., Refsum H., Kooner J.S. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000, 102:2479-2483.
11. Chen C., Conklin B.S., Ren Z., Zhong D.S. Homocysteine decreases endothelium-dependent vasorelaxation in porcine arteries. J. Surg. Res. 2002, 102:22-30.
12. Chen T.F., Huang R.F., Lin S.E., Lu J.F., Tang M.C., Chiu M.J. Folic acid potentiates the effect of memantine on spatial learning and neuronal protection in an Alzheimer's disease transgenic model. J. Alzheimers Dis. 2010, 20:607-615.
13. Chen Z., Karaplis A.C., Ackerman S.L., Pogribny I.P., Melnyk S., Lussier-Cacan S., Chen M.F., Pai A., John S.W., Smith R.S., Bottiglieri T., Bagley P., Selhub J., Rudnicki M.A., James S.J., Rozen R. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet. 2001, 10:433-443.
14. Choe Y.M., Sohn B.K., Choi H.J., Byun M.S., Seo E.H., Han J.Y., Kim Y.K., Yoon E.J., Lee J.M., Park J., Woo J.I., Lee D.Y. Association of homocysteine with hippocampal volume independent of cerebral amyloid and vascular burden. Neurobiol. Aging 2014, 35:1519-1525.
15. Clarke R., Bennett D., Parish S., Lewington S., Skeaff M., Eussen S.J., Lewerin C., Stott D.J., Armitage J., Hankey G.J., Lonn E., Spence J.D., Galan P., de Groot L.C., Halsey J., Dangour A.D., Collins R., Grodstein F. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am. J. Clin. Nutr. 2014, 100:657-666.
16. Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., Ueland P.M. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 1998, 55:1449-1455.
17. Dalton M.L., Gadson P.F., Wrenn R.W., Rosenquist T.H. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J. 1997, 11:703-711.
18. Dayal S., Bottiglieri T., Arning E., Maeda N., Malinow M.R., Sigmund C.D., Heistad D.D., Faraci F.M., Lentz S.R. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ. Res. 2001, 88:1203-1209.
19. Dayal S., Lentz S.R. Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1596-1605.
20. de Jager C.A., Oulhaj A., Jacoby R., Refsum H., Smith A.D. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int. J. Geriatr. Psychiatry 2012, 27:592-600.
21. de Lau L.M., van Meurs J.B., Uitterlinden A.G., Smith A.D., Refsum H., Johnston C., Breteler M.M. Genetic variation in homocysteine metabolism, cognition, and white matter lesions. Neurobiol. Aging 2010, 31:2020-2022.
22. Douaud G., Refsum H., de Jager C.A., Jacoby R., Nichols T.E., Smith S.M., Smith A.D. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:9523-9528.
23. Durga J., van Boxtel M.P., Schouten E.G., Kok F.J., Jolles J., Katan M.B., Verhoef P. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 2007, 369:208-216.
24. Eberhardt R.T., Forgione M.A., Cap A., Leopold J.A., Rudd M.A., Trolliet M., Heydrick S., Stark R., Klings E.S., Moldovan N.I., Yaghoubi M., Goldschmidt-Clermont P.J., Farber H.W., Cohen R., Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J. Clin. Invest. 2000, 106:483-491.
25. Egbuta J.O., Griffiths R. Binding of [3H]muscimol to calf cerebrocortical synaptic membranes and the effects of sulphur-containing convulsant and non-convulsant compounds. Neurochem. Res. 1987, 12:589-595.
26. 2+ and the potentiation by serum albumin. Brain Res. 1991, 560:282-290.
27. Emara M., Cheung P.Y. Inhibition of sulfur compounds and antioxidants on MMP-2 and -9 at the activity level found during neonatal hypoxia-reoxygenation. Eur. J. Pharmacol. 2006, 544:168-173.
28. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju C.V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002, 359:1283-1290.
29. Ernest S., Hosack A., O'Brien W.E., Rosenblatt D.S., Nadeau J.H. Homocysteine levels in A/J and C57BL/6J mice: genetic, diet, gender, and parental effects. Physiol. Genomics 2005, 21:404-410.
30. Esiri M.M., Wilcock G.K., Morris J.H. Neuropathological assessment of the lesions of significance in vascular dementia. J. Neurol. Neurosurg. Psychiatry 1997, 63:749-753.
31. Fernando M.S., Simpson J.E., Matthews F., Brayne C., Lewis C.E., Barber R., Kalaria R.N., Forster G., Esteves F., Wharton S.B., Shaw P.J., O'Brien J.T., Ince P.G. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 2006, 37:1391-1398.
32. Firbank M.J., Narayan S.K., Saxby B.K., Ford G.A., O'Brien J.T. Homocysteine is associated with hippocampal and white matter atrophy in older subjects with mild hypertension. Int. Psychogeriatr. 2010, 1-8.
33. Ford A.H., Almeida O.P. Effect of homocysteine lowering treatment on cognitive function: a systematic review and meta-analysis of randomized controlled trials. J. Alzheimers Dis. 2012, 29:133-149.
34. Giwa M.O., Williams J., Elderfield K., Jiwa N.S., Bridges L.R., Kalaria R.N., Markus H.S., Esiri M.M., Hainsworth A.H. Neuropathologic evidence of endothelial changes in cerebral small vessel disease. Neurology 2012, 78:167-174.
35. Gorelick P.B., Scuteri A., Black S.E., DeCarli C., Greenberg S.M., Iadecola C., Launer L.J., Laurent S., Lopez O.L., Nyenhuis D., Petersen R.C., Schneider J.A., Tzourio C., Arnett D.K., Bennett D.A., Chui H.C., Higashida R.T., Lindquist R., Nilsson P.M., Roman G.C., Sellke F.W., Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/American stroke association. Stroke 2011, 42:2672-2713.
36. Gorman A., Griffiths R. Sulphur-containing excitatory amino acid-stimulated inositol phosphate formation in primary cultures of cerebellar granule cells is mediated predominantly by N-methyl-d-aspartate receptors. Neuroscience 1994, 59:299-308.
37. Gortz P., Hoinkes A., Fleischer W., Otto F., Schwahn B., Wendel U., Siebler M. Implications for hyperhomocysteinemia: not homocysteine but its oxidized forms strongly inhibit neuronal network activity. J. Neurol. Sci. 2004, 218:109-114.
38. Griffiths R., Grieve A., Dunlop J., Damgaard I., Fosmark H., Schousboe A. Inhibition by excitatory sulphur amino acids of the high-affinity l-glutamate transporter in synaptosomes and in primary cultures of cortical astrocytes and cerebellar neurons. Neurochem. Res. 1989, 14:333-343.
39. Gupta S., Kuhnisch J., Mustafa A., Lhotak S., Schlachterman A., Slifker M.J., Klein-Szanto A., High K.A., Austin R.C., Kruger W.D. Mouse models of cystathionine beta-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia. FASEB J. 2009, 23:883-893.
40. Hainsworth A.H., Oommen A.T., Bridges L.R. Endothelial cells and human cerebral small vessel disease. Brain Pathol. 2015, 25:44-50.
41. Hajjar K.A. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J. Clin. Invest. 1993, 91:2873-2879.
42. Harker L.A., Harlan J.M., Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ. Res. 1983, 53:731-739.
43. Harpel P.C., Chang V.T., Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:10193-10197.
44. Hassan A., Hunt B.J., O'Sullivan M., Bell R., D'Souza R., Jeffery S., Bamford J.M., Markus H.S. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004, 127:212-219.
45. Hassan A., Hunt B.J., O'Sullivan M., Parmar K., Bamford J.M., Briley D., Brown M.M., Thomas D.J., Markus H.S. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003, 126:424-432.
46. Heider I., Lehmensiek V., Lenk T., Muller T., Storch A. Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures. J. Neural Transm. 2004, 1-13. Suppl.
47. Hogervorst E., Ribeiro H.M., Molyneux A., Budge M., Smith A.D. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch. Neurol. 2002, 59:787-793.
48. Homocysteine studies collaboration, homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022.
49. Hooshmand B., Polvikoski T., Kivipelto M., Tanskanen M., Myllykangas L., Erkinjuntti T., Makela M., Oinas M., Paetau A., Scheltens P., van Straaten E.C., Sulkava R., Solomon A. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain 2013, 136:2707-2716.
50. Hultberg B. Extracellular concentration of homocysteine in human cell lines is influenced by specific inhibitors of cyst(e)ine transport. Clin. Chem. Lab. Med. 2004, 42:378-383.
51. Iosifescu D.V., Papakostas G.I., Lyoo I.K., Lee H.K., Renshaw P.F., Alpert J.E., Nierenberg A., Fava M. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (part I). Psychiatry Res. 2005, 140:291-299.
52. Jacobsen D.W. Homocysteine and vitamins in cardiovascular disease. Clin. Chem. 1998, 44:1833-1843.
53. Jamaluddin M.D., Chen I., Yang F., Jiang X., Jan M., Liu X., Schafer A.I., Durante W., Yang X., Wang H. Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood 2007, 110:3648-3655.
54. Jara-Prado A., Ortega-Vazquez A., Martinez-Ruano L., Rios C., Santamaria A. Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition. Neurotox. Res. 2003, 5:237-243.
55. Jerneren F., Elshorbagy A.K., Oulhaj A., Smith S.M., Refsum H., Smith A.D. Brain atrophy in cognitively impaired elderly: the importance of long-chain omega-3 fatty acids and B vitamin status in a randomized controlled trial. Am. J. Clin. Nutr. 2015, 102:215-221.
56. Jiang X., Yang F., Brailoiu E., Jakubowski H., Dun N.J., Schafer A.I., Yang X., Durante W., Wang H. Differential regulation of homocysteine transport in vascular endothelial and smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1976-1983.
57. Jiang X., Yang F., Tan H., Liao D., Bryan R.M., Randhawa J.K., Rumbaut R.E., Durante W., Schafer A.I., Yang X., Wang H. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2515-2521.
58. Jiwa N.S., Garrard P., Hainsworth A.H. Experimental models of vascular dementia and vascular cognitive impairment. A systematic review. J. Neurochem. 2010, 115:814-828.
59. Kamath A.F., Chauhan A.K., Kisucka J., Dole V.S., Loscalzo J., Handy D.E., Wagner D.D. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood 2006, 107:591-593.
60. Kang J.H., Cook N., Manson J., Buring J.E., Albert C.M., Grodstein F. A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. Am. J. Clin. Nutr. 2008, 88:1602-1610.
61. Khan U., Crossley C., Kalra L., Rudd A., Wolfe C.D., Collinson P., Markus H.S. Homocysteine and its relationship to stroke subtypes in a UK black population: the south London ethnicity and stroke study. Stroke 2008, 39:2943-2949.
62. Khan U., Hassan A., Vallance P., Markus H.S. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke 2007, 38:411-413.
63. Kim J.M., Lee H., Chang N. Hyperhomocysteinemia due to short-term folate deprivation is related to electron microscopic changes in the rat brain. J. Nutr. 2002, 132:3418-3421.
64. Kloppenborg R.P., Geerlings M.I., Visseren F.L., Mali W.P., Vermeulen M., van der Graaf Y., Nederkoorn P.J. Homocysteine and progression of generalized small-vessel disease: the SMART-MR study. Neurology 2014, 82:777-783.
65. Kokame K., Kato H., Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. GRP78/BiP and novel genes. J. Biol. Chem. 1996, 271:29659-29665.
66. Kraus J.P., Janosik M., Kozich V., Mandell R., Shih V., Sperandeo M.P., Sebastio G., de F.R., Andria G., Kluijtmans L.A., Blom H., Boers G.H., Gordon R.B., Kamoun P., Tsai M.Y., Kruger W.D., Koch H.G., Ohura T., Gaustadnes M. Cystathionine beta-synthase mutations in homocystinuria. Hum. Mutat. 1999, 13:362-375.
67. Lang D., Kredan M.B., Moat S.J., Hussain S.A., Powell C.A., Bellamy M.F., Powers H.J., Lewis M.J. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler. Thromb. Vasc. Biol. 2000, 20:422-427.
68. Lee H., Kim J.M., Kim H.J., Lee I., Chang N. Folic acid supplementation can reduce the endothelial damage in rat brain microvasculature due to hyperhomocysteinemia. J. Nutr. 2005, 135:544-548.
69. Lee S.J., Kim K.M., Namkoong S., Kim C.K., Kang Y.C., Lee H., Ha K.S., Han J.A., Chung H.T., Kwon Y.G., Kim Y.M. Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine. J. Biol. Chem. 2005, 280:5781-5788.
70. Lentz S.R., Malinow M.R., Piegors D.J., Bhopatkar-Teredesai M., Faraci F.M., Heistad D.D. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2930-2934.
71. Lentz S.R., Sobey C.G., Piegors D.J., Bhopatkar M.Y., Faraci F.M., Malinow M.R., Heistad D.D. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J. Clin. Invest. 1996, 98:24-29.
72. Liu G., Nellaiappan K., Kagan H.M. Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria. J. Biol. Chem. 1997, 272:32370-32377.
73. Liu X., Luo F., Li J., Wu W., Li L., Chen H. Homocysteine induces connective tissue growth factor expression in vascular smooth muscle cells. J. Thromb. Haemost. 2008, 6:184-192.
74. Liu Z., Luo H., Zhang L., Huang Y., Liu B., Ma K., Feng J., Xie J., Zheng J., Hu J., Zhan S., Zhu Y., Xu Q., Kong W., Wang X. Hyperhomocysteinemia exaggerates adventitial inflammation and angiotensin II-induced abdominal aortic aneurysm in mice. Circ. Res. 2012, 111:1261-1273.
75. Luchowska E., Luchowski P., Paczek R., Ziembowicz A., Kocki T., Turski W.A., Wielosz M., Lazarewicz J., Urbanska E.M. Dual effect of dl-homocysteine and S-adenosylhomocysteine on brain synthesis of the glutamate receptor antagonist, kynurenic acid. J. Neurosci. Res. 2005, 79:375-382.
76. Majors A., Ehrhart L.A., Pezacka E.H. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2074-2081.
77. Markus H.S. Genes, endothelial function and cerebral small vessel disease in man. Exp. Physiol. 2008, 93:121-127.
78. McCaddon A., Miller J.W. Assessing the Association Between Homocysteine and Cognition: Reflections on Bradford Hill, Meta-analyses, and Causality 2015, Nutr, Rev.
79. McMahon J.A., Green T.J., Skeaff C.M., Knight R.G., Mann J.I., Williams S.M. A controlled trial of homocysteine lowering and cognitive performance. N. Engl. J. Med. 2006, 354:2764-2772.
80. Mikael L.G., Wang X.L., Wu Q., Jiang H., Maclean K.N., Rozen R. Hyperhomocysteinemia is associated with hypertriglyceridemia in mice with methylenetetrahydrofolate reductase deficiency. Mol. Genet. Metab. 2009, 98:187-194.
81. Moorhouse P., Rockwood K. Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol. 2008, 7:246-255.
82. MRC-CFAS Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001, 357:169-175.
83. Muthuramu I., Jacobs F., Singh N., Gordts S.C., De Geest B. Selective homocysteine lowering gene transfer improves infarct healing, attenuates remodelling, and enhances diastolic function after myocardial infarction in mice. PLoS ONE 2013, 8:e63710.
84. Muthuramu I., Singh N., Amin R., Nefyodova E., Debasse M., Van H., Jacobs I.,.F., De Geest B. Selective homocysteine-lowering gene transfer attenuates pressure overload-induced cardiomyopathy via reduced oxidative stress. J. Mol. Med. 2015, 93:609-618. (Berl).
85. Neves M.F., Endemann D., Amiri F., Virdis A., Pu Q., Rozen R., Schiffrin E.L. Small artery mechanics in hyperhomocysteinemic mice: effects of angiotensin II. J. Hypertens. 2004, 22:959-966.
86. Nishinaga M., Ozawa T., Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J. Clin. Invest. 1993, 92:1381-1386.
87. O'Brien J.T., Erkinjuntti T., Reisberg B., Roman G., Sawada T., Pantoni L., Bowler J.V., Ballard C., DeCarli C., Gorelick P.B., Rockwood K., Burns A., Gauthier S., DeKosky S.T. Vascular cognitive impairment. Lancet Neurol. 2003, 2:89-98.
88. Oulhaj A., Refsum H., Beaumont H., Williams J., King E., Jacoby R., Smith A.D. Homocysteine as a predictor of cognitive decline in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2010, 25:82-90.
89. Outinen P.A., Sood S.K., Pfeifer S.I., Pamidi S., Podor T.J., Li J., Weitz J.I., Austin R.C. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 1999, 94:959-967.
90. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010, 9:689-701.
91. Pirchl M., Ullrich C., Humpel C. Differential effects of short- and long-term hyperhomocysteinaemia on cholinergic neurons, spatial memory and microbleedings in vivo in rats. Eur. J. Neurosci. 2010, 32:1516-1527.
92. Prins N.D., Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat. Rev. Neurol. 2015, 11:157-165.
93. Pullan L.M., Olney J.W., Price M.T., Compton R.P., Hood W.F., Michel J., Monahan J.B. Excitatory amino acid receptor potency and subclass specificity of sulfur-containing amino acids. J. Neurochem. 1987, 49:1301-1307.
94. Rajagopalan P., Hua X., Toga A.W., Jack C.R., Weiner M.W., Thompson P.M. Homocysteine effects on brain volumes mapped in 732 elderly individuals. Neuroreport 2011, 22:391-395.
95. Riba R., Nicolaou A., Troxler M., Homer-Vaniasinkam S., Naseem K.M. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis 2004, 175:69-75.
96. Sagara Y., Ishige K., Tsai C., Maher P. Tyrphostins protect neuronal cells from oxidative stress. J. Biol. Chem. 2002, 277:36204-36215.
97. Saposnik G. The role of vitamin B in stroke prevention: a journey from observational studies to clinical trials and critique of the VITAmins TO Prevent Stroke (VITATOPS). Stroke 2011, 42:838-842.
98. Saposnik G., Ray J.G., Sheridan P., McQueen M., Lonn E. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009, 40:1365-1372.
99. Schmidt R., Seiler S., Loitfelder M. Longitudinal Change of Small-vessel Disease-Related Brain Abnormalities 2015, J. Cereb, Blood Flow Metab.
100. Scott T.M., Tucker K.L., Bhadelia A., Benjamin B., Patz S., Bhadelia R., Liebson E., Price L.L., Griffith J., Rosenberg I., Folstein M.F. Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders. Am. J. Geriatr. Psychiatry 2004, 12:631-638.
101. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 2002, 346:476-483.
102. Shastry S., Tyagi N., Hayden M.R., Tyagi S.C. Proteomic analysis of homocysteine inhibition of microvascular endothelial cell angiogenesis. Cell Mol. Biol. (Noisy-le-Grand) 2004, 50:931-937.
103. Shastry S., Tyagi S.C. Homocysteine induces metalloproteinase and shedding of beta-1 integrin in microvessel endothelial cells. J. Cell. Biochem. 2004, 93:207-213.
104. Smallwood A., Oulhaj A., Joachim C., Christie S., Sloan C., Smith A.D., Esiri M. Cerebral subcortical small vessel disease and its relation to cognition in elderly subjects: a pathological study in the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Neuropathol. Appl. Neurobiol. 2012, 38:337-343.
105. Smith A.D. The worldwide challenge of the dementias: a role for B vitamins and homocysteine?. Food Nutr. Bull. 2008, 29:S143-S172.
106. Smith A.D., Smith S.M., de Jager C.A., Whitbread P., Johnston C., Agacinski G., Oulhaj A., Bradley K.M., Jacoby R., Refsum H. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE 2010, 5.
107. Snyder H.M., Corriveau R.A., Craft S., Faber J.E., Greenberg S.M., Knopman D., Lamb B.T., Montine T.J., Nedergaard M., Schaffer C.B., Schneider J.A., Wellington C., Wilcock D.M., Zipfel G.J., Zlokovic B., Bain L.J., Bosetti F., Galis Z.S., Koroshetz W., Carrillo M.C. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement. 2014, S1552-5260(14)02862-3.
108. Sudduth T.L., Powell D.K., Smith C.D., Greenstein A., Wilcock D.M. Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. J. Cereb. Blood Flow Metab. 2013, 33:708-715.
109. Tawakol A., Omland T., Gerhard M., Wu J.T., Creager M.A. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997, 95:1119-1121.
110. Troen A.M. The central nervous system in animal models of hyperhomocysteinemia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2005, 29:1140-1151.
111. Troen A.M., Shea-Budgell M., Shukitt-Hale B., Smith D.E., Selhub J., Rosenberg I.H. B-vitamin deficiency causes hyperhomocysteinemia and vascular cognitive impairment in mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:12474-12479.
112. Tsai J.C., Perrella M.A., Yoshizumi M., Hsieh C.M., Haber E., Schlegel R., Lee M.E. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:6369-6373.
113. Tsai J.C., Wang H., Perrella M.A., Yoshizumi M., Sibinga N.E., Tan L.C., Haber E., Chang T.H., Schlegel R., Lee M.E. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J. Clin. Invest. 1996, 97:146-153.
114. van Dijk E.J., Prins N.D., Vrooman H.A., Hofman A., Koudstaal P.J., Breteler M.M. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 2008, 39:2712-2719.
115. Veeranki S., Tyagi S.C. Defective homocysteine metabolism: potential implications for skeletal muscle malfunction. Int. J. Mol. Sci. 2013, 14:15074-15091.
116. Verdelho A., Madureira S., Moleiro C., Ferro J.M., Santos C.O., Erkinjuntti T., Pantoni L., Fazekas F., Visser M., Waldemar G., Wallin A., Hennerici M., Inzitari D. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology 2010, 75:160-167.
117. Vermeer S.E., van Dijk E.J., Koudstaal P.J., Oudkerk M., Hofman A., Clarke R., Breteler M.M. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan study. Ann. Neurol. 2002, 51:285-289.
118. Wald D.S., Kasturiratne A., Simmonds M. Effect of folic acid, with or without other B vitamins, on cognitive decline: meta-analysis of randomized trials. Am. J. Med. 2010, 123:522-527.
119. Wang H., Yoshizumi M., Lai K., Tsai J.C., Perrella M.A., Haber E., Lee M.E. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J. Biol. Chem. 1997, 272:25380-25385.
120. Wang L., Jhee K.H., Hua X., DiBello P.M., Jacobsen D.W., Kruger W.D. Modulation of cystathionine beta-synthase level regulates total serum homocysteine in mice. Circ. Res. 2004, 94:1318-1324.
121. Watanabe M., Osada J., Aratani Y., Kluckman K., Reddick R., Malinow M.R., Maeda N. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:1585-1589.
122. Weiss N., Heydrick S., Zhang Y.Y., Bierl C., Cap A., Loscalzo J. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2002, 22:34-41.
123. Wright C.B., Paik M.C., Brown T.R., Stabler S.P., Allen R.H., Sacco R.L., DeCarli C. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan study. Stroke 2005, 36:1207-1211.
124. Yeganeh F., Nikbakht F., Bahmanpour S., Rastegar K., Namavar R. Neuroprotective effects of NMDA and group I metabotropic glutamate receptor antagonists against neurodegeneration induced by homocysteine in rat hippocampus: in vivo study. J. Mol. Neurosci. 2013, 50:551-557.
125. Zeng X., Dai J., Remick D.G., Wang X. Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ. Res. 2003, 93:311-320.